NCT05106192Withdrawn
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Source: ClinicalTrials.gov · Last updated 12 Jun 2025
Reason given: Study closed prior to enrollment of first participant
Brief summary (registry, in English)
A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.
- Status (registry)
- Withdrawn
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 12 Oct 2021
- Start date
- 1 Apr 2022
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Case Comprehensive Cancer Center
- Diseases
- Follicular lymphoma
- NCT number
- NCT05106192
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.
- Use of topical corticosteroids to target lesions within 1 week prior to baseline visit
- Use of radiation therapy to target lesions within 1 week prior to baseline visit
Other illness
- Known allergy or hypersensitivity to triamcinolone acetonide
- Known allergy to topical bexarotene or topical nitrogen mustard
- Diagnosis of erythrodermic mycosis fungoides or Sezary syndrome
Other
- Inability to provide informed consent
Who the study is looking for
- > 18 years of age
- Diagnosed with primary cutaneous lymphoma defined by either:
- A board-certified dermatologist, OR
- Dermatology Nurse Practitioner, OR
- Skin punch biopsy
- The presence of plaque-type primary cutaneous lymphoma lesions with at least two plaques that are at least two cm² in areas of the trunk, buttocks, or extremities that are either:
- Symmetrically located on contralateral body site OR
- Within the same body site but separated by ≥ 1 cm
- Both plaques must be similar in size as much as possible
- Able to give informed consent under IRB approval procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.